Published online Jan 14, 2023. doi: 10.3748/wjg.v29.i2.272
Peer-review started: September 23, 2022
First decision: November 18, 2022
Revised: December 1, 2022
Accepted: December 21, 2022
Article in press: December 21, 2022
Published online: January 14, 2023
Processing time: 104 Days and 21.2 Hours
There is great heterogeneity among inflammatory bowel disease (IBD) patients in terms of pathogenesis, clinical manifestation, response to treatment, and prognosis, which requires the individualized and precision management of patients. Many studies have focused on prediction biomarkers and models for assessing IBD disease type, activity, severity, and prognosis. During the era of biologics, how to predict the response and side effects of patients to different treatments and how to quickly recognize the loss of response have also become important topics. Multiomics is a promising area for investigating the complex network of IBD pathogenesis. Integrating numerous amounts of data requires the use of artificial intelligence.
Core Tip: Inflammatory bowel diseases (IBDs) exhibit different pathogeneses and clinical manifestations. Making precise and appropriate therapeutic decisions according to the condition of each patient remains challenging. We summarize the clustering strategies, the approaches used to apply multiomics and artificial intelligence to IBD precision management.